2024
Michigan Cancer and Research on the Environment Study (MI-CARES): A Cohort to Investigate Environmental Injustice and Health Disparities in Cancer
Phung M, Khoja L, Getz K, Salvatore M, Uphold H, Colacino J, Mondul A, Mukherjee B, Dolinoy D, Pearce C. Michigan Cancer and Research on the Environment Study (MI-CARES): A Cohort to Investigate Environmental Injustice and Health Disparities in Cancer. ISEE Conference Abstracts 2024, 2024 DOI: 10.1289/isee.2024.1830.Peer-Reviewed Original Research
2023
A framework for assessing interactions for risk stratification models: the example of ovarian cancer
Phung M, Lee A, McLean K, Anton-Culver H, Bandera E, Carney M, Chang-Claude J, Cramer D, Doherty J, Fortner R, Goodman M, Harris H, Jensen A, Modugno F, Moysich K, Pharoah P, Qin B, Terry K, Titus L, Webb P, Wu A, Zeinomar N, Ziogas A, Berchuck A, Cho K, Hanley G, Meza R, Mukherjee B, Pike M, Pearce C, Trabert B. A framework for assessing interactions for risk stratification models: the example of ovarian cancer. Journal Of The National Cancer Institute 2023, 115: 1420-1426. PMID: 37436712, PMCID: PMC10637032, DOI: 10.1093/jnci/djad137.Peer-Reviewed Original ResearchConceptsFamily history of ovarian cancerOvarian Cancer Association ConsortiumHistory of ovarian cancerFirst-degree family historyMenopausal statusRisk stratification modelCase-control studyRisk prediction modelOvarian cancerDisease riskAccurate risk stratification modelsStratification modelRisk/protective factorsDepot medroxyprogesterone acetate useProtective factorsFactor analysisRiskComprehensive analysis of interactionsCancerAcetate useUnequivocal riskStatusBreastfeedingAnalysis of interactionsPairwise interactions
2021
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported data
2020
Fusobacterium nucleatum infection correlates with two types of microsatellite alterations in colorectal cancer and triggers DNA damage
Okita Y, Koi M, Takeda K, Ross R, Mukherjee B, Koeppe E, Stoffel E, Galanko J, McCoy A, Keku T, Okugawa Y, Kitajima T, Toiyama Y, Martens E, Carethers J. Fusobacterium nucleatum infection correlates with two types of microsatellite alterations in colorectal cancer and triggers DNA damage. Gut Pathogens 2020, 12: 46. PMID: 33005238, PMCID: PMC7526104, DOI: 10.1186/s13099-020-00384-3.Peer-Reviewed Original ResearchMicrosatellite instability-highCpG island hypermethylation phenotypeColorectal cancerMicrosatellite alterationsFusobacterium nucleatum infectionInflammatory tumor microenvironmentSubtypes of colorectal cancerDNA double strand breaksColorectal cancer cohortMicrosatellite instability-lowTumor microenvironmentFn infectionColorectal cancer tissuesHypermethylation phenotypeElevated levelsInfected cellsCancerInfectionAlterationsDouble strand breaksAssociated with microsatellite instability-highStrand breaks
2019
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Caram M, Ross R, Lin P, Mukherjee B. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. JAMA Network Open 2019, 2: e192589. PMID: 31002323, PMCID: PMC6481456, DOI: 10.1001/jamanetworkopen.2019.2589.Peer-Reviewed Original ResearchConceptsMinimally symptomatic metastatic castration-resistant prostate cancerSipuleucel-TProstate cancerSymptomatic metastatic castration-resistant prostate cancerDatabase of commercially insured patientsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAge of patientsRetrospective cohort studyFactors associated with useAssociated with patientsCommercially insured patientsPatterns of treatmentConcurrent therapyTreated patientsCohort studyMultivariate analysisCancer therapyTherapyPatientsPhysician factorsCancerBarriers to treatmentBinomial logistic regressionLogistic regression
2018
Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer.
Caram M, Wang S, Cheng P, Griggs J, Lin P, Mukherjee B. Patient and provider variables associated with variation in the systemic treatment of advanced prostate cancer. Journal Of Clinical Oncology 2018, 36: e17019-e17019. DOI: 10.1200/jco.2018.36.15_suppl.e17019.Peer-Reviewed Original ResearchTemporal and geographic variation in the systemic treatment of advanced prostate cancer
Caram M, Estes J, Griggs J, Lin P, Mukherjee B. Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer 2018, 18: 258. PMID: 29510667, PMCID: PMC5840834, DOI: 10.1186/s12885-018-4166-3.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerFirst-line therapyProstate cancerSystemic treatmentFirst-lineSystemic treatment of advanced prostate cancerTreatment of metastatic castration-resistant prostate cancerTreatment of advanced prostate cancerResultsOur final analysisAdvanced prostate cancerFirst line therapyFood and Drug AdministrationNational insurance providerLine therapySequence of treatmentTreatment patternsDisease courseStudy cohortPrescription ratesPrescribed drugsDrug AdministrationIncreased survivalCancerTherapy
2015
Genome-wide association study of colorectal cancer identifies six new susceptibility loci
Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, Hsu L, Huang SC, Fischer CP, Harju JF, Idos GE, Lejbkowicz F, Manion FJ, McDonnell K, McNeil CE, Melas M, Rennert HS, Shi W, Thomas DC, Van Den Berg DJ, Hutter CM, Aragaki AK, Butterbach K, Caan BJ, Carlson CS, Chanock SJ, Curtis KR, Fuchs CS, Gala M, Giovannucci EL, Gogarten SM, Hayes RB, Henderson B, Hunter DJ, Jackson RD, Kolonel LN, Kooperberg C, Küry S, LaCroix A, Laurie CC, Laurie CA, Lemire M, Levine D, Ma J, Makar KW, Qu C, Taverna D, Ulrich CM, Wu K, Kono S, West DW, Berndt SI, Bezieau S, Brenner H, Campbell PT, Chan AT, Chang-Claude J, Coetzee GA, Conti DV, Duggan D, Figueiredo JC, Fortini BK, Gallinger SJ, Gauderman WJ, Giles G, Green R, Haile R, Harrison TA, Hoffmeister M, Hopper JL, Hudson TJ, Jacobs E, Iwasaki M, Jee SH, Jenkins M, Jia WH, Joshi A, Li L, Lindor NM, Matsuo K, Moreno V, Mukherjee B, Newcomb PA, Potter JD, Raskin L, Rennert G, Rosse S, Severi G, Schoen RE, Seminara D, Shu XO, Slattery ML, Tsugane S, White E, Xiang YB, Zanke BW, Zheng W, Le Marchand L, Casey G, Gruber SB, Peters U. Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nature Communications 2015, 6: 7138. PMID: 26151821, PMCID: PMC4967357, DOI: 10.1038/ncomms8138.Peer-Reviewed Original ResearchConceptsNew susceptibility lociAssociation studiesSusceptibility lociSignificant genetic lociGenome-wide association studiesGenome-wide thresholdCommon genetic variantsRare pathogenic mutationsTwo-stage association studyGenetic lociGenetic epidemiology studiesGenetic variantsLociUnderlying biological mechanismsPathogenic mutationsBiological mechanismsAsian ConsortiumGenetic susceptibilityMutationsAdditional insightColorectal cancerCancerVariants
2013
Investigating parent of origin effects (POE) and anticipation in Irish Lynch syndrome kindreds.
Farrell M, Hughes D, Schmid J, Boonstra P, Mukherjee B, Walshe M, Mac Mathuna P, Green A, Gallagher D. Investigating parent of origin effects (POE) and anticipation in Irish Lynch syndrome kindreds. Journal Of Clinical Oncology 2013, 31: 1542-1542. DOI: 10.1200/jco.2013.31.15_suppl.1542.Peer-Reviewed Original ResearchAffected parent-child pairsParent-of-origin effectsParent-child pairsLS familiesLynch syndromePaired t-testInvestigate parent-of-origin effectsCancer genetics centresLynch syndrome kindredHospital-based registryT-testOffspring of affected mothersRisk of diseaseGenetic centresEvidence of anticipationInvestigate parentGenetic anticipationDisease allelesAffected fatherStatistical significanceEarly onsetMothersSeverity of diseaseFamilyCancer